search 2013 adfgs

Funding Opportunities and Resources

Access to capital is a major hurdle for biotechnology companies of every size.  BioNJ is pleased to offer the following list of funding opportunities to its Members.

Horizon 2020

The EU Framework Programme for Research and Innovation

Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

Please click here to learn more.

Michael J. Fox Foundation Open Funding Programs

Access Data & Biospecimens

Deadline: No deadline; applications accepted anytime
Access valuable data, biospecimens and tissue resources from several pre-clinical and clinical efforts

Rapid Response Innovation Awards Program

Deadline: No deadline; applications accepted anytime
One-year grants to jump start new ideas in PD research. An Edmond J. Safra Core Program for PD Research.

Target Validation

Deadline: Pre-Proposals Due: October 30, 2013 – 6:00 pm US ET
Two-year grants to nominate new therapeutic targets for Parkinson’s disease. An Edmond J. Safra Core Program for PD Research.

Therapeutic Pipeline Program

Deadline: Pre-Proposals Due: October 30, 2013 – 6:00 pm US ET
Our flagship program for supporting critical preclinical and clinical development of promising Parkinson’s therapies. An Edmond J. Safra Core Program for PD Research.

Dyskinesia Challenge 2013

Deadline: No deadline; applications accepted anytime.
One-year grants to identify and validate novel dyskinesia targets.

LRRK2 Challenge 2013

Deadline: No deadline; applications accepted anytime.
One-year grants to uncover new insight into LRRK2 parkinsonism.

Neurotrophic Factors Challenge 2013

Deadline: No deadline; applications accepted anytime.
One-year grants to accelerate development of neurotrophic factor therapies.

Christie Administration Awards $2.9 Million in Grants for Spinal Cord Research

The New Jersey Commission on Spinal Cord Research has awarded more than $2.9 million in grants to fund the development of treatments and cures for paralysis and other spinal cord related diseases and injuries.

“These grant funds will support and incentivize research and development opportunities in New Jersey with the goal of improving the lives of people suffering from paralysis due to disease or injury,” said New Jersey Health Commissioner Mary E. O’Dowd. “By continuing our support of this research, there will be great advancements in medical science that may one day lead to a cure for people with these debilitating conditions.”

Approximately 6,000 New Jersey residents suffer from traumatic injuries or diseases that damage the spinal cord and approximately 250 residents suffer spinal cord injuries that require hospitalization each year.

Nationally, the number of people living with spinal cord injuries totals approximately 1,275,000 with the costs of these injuries estimated at $40.5 billion.

The Commission was created with the mission to stimulate spinal cord research in New Jersey and recruit new scientists to the field through the funding of research projects and fellowships at qualifying institutions throughout the state. Since 1999, the Commission has awarded more than $38. 9 million in awards for research into spinal cord related disease and injuries. In 2013, thirty-six applications were submitted with requests for funding totaling nearly $10.2 million.

A wide range of grant opportunities are offered, including: Individual Research Grants; Post-doctoral and Graduate Fellowships; Exploratory Research Grants and Spinal Cord Techniques Training Travel Grants.

The 2012 New Jersey Commission on Spinal Cord Research Annual Report is available at: http://www.state.nj.us/health/spinalcord/documents/2012_annual_report.pdf

Complete information on the grant recipient projects and funding is available at: http://nj.gov/health/spinalcord/documents/2013_grant_directory.pdf

To apply for future research grants, access grant applications, find out application deadlines, and to obtain additional information on the New Jersey Commission on Spinal Cord Research, visit the website at www.state.nj.us/health/spinalcord. For telephone inquiries, please call 609-292-4055.

Christie Administration Awards $3.8 Million in Grants for Traumatic Brain Injury Research

New Jersey Health Commissioner Mary O’Dowd announced today more than $3.8 million in grants for research to develop treatments and cures for disabilities associated with traumatic brain injury. These grant awards are approved by the New Jersey Commission on Brain Injury Research.

“New Jersey has some of the finest medical institutions and research facilities the nation has to offer,” said Commissioner O’Dowd. “With this funding, the Department of Health is working to stimulate advancement in care that will improve the quality of life for people with brain injuries.”

In New Jersey, approximately 175,000 New Jersey residents suffer from traumatic injuries that damage the brain, and 12,000 new injuries occur each year that require inpatient or outpatient treatment.

The economic consequences of physical disabilities due to traumatic brain injury, including medical and long-term care costs, are estimated at $48 billion annually in the United States.

Since the Commission was created in 2004, more than $21 million has been awarded in New Jersey to research and develop effective treatment and cures for the disabilities associated with traumatic brain injury. In 2013, thirty-eight applicants requested funding totaling more than $15.4 million.

A wide range of grant opportunities are offered including: Individual Research Grants; Post-doctoral and Graduate Fellowships; Pilot Research Grants and Programmatic Multi-Investigator Research Grants.

The 2012 New Jersey Commission on Brain Injury Annual Report is available at: http://www.state.nj.us/health/njcbir/documents/2012_annual_report.pdf

Complete information on the grant recipient projects and funding is available at: http://nj.gov/health/njcbir/documents/2013_brain_injury_grants.pdf

To apply for future research grants, access grant applications, find out application deadlines, and to obtain additional information on the New Jersey Commission on Brain Injury Research, visit the website at http://www.nj.gov/health/njcbir. For telephone inquiries, please call 609-633-6465.

NewSpring Capital Raises $250 Million Growth Equity Fund

Radnor, PA - May 3, 2013 – NewSpring Capital (“NSC”), a leading U.S. private equity firm, announced today the closing of its third growth equity fund, NewSpring Growth Capital III, L.P. (“NSG III” or the “Fund”), with total commitments exceeding the Fund’s target of $200 million and reaching its hard cap of $250 million.  NSG III will seek to build upon the successes of its predecessor funds, NewSpring Growth Capital, L.P., a $136 million growth equity fund and NewSpring Growth Capital II, L.P., a $163 million growth equity fund.  Since its inception in 1999, NSC has raised seven funds across its growth, healthcare and mezzanine platforms, with combined assets under management of over $950 million.

“We are extremely pleased with the continued support we receive from our existing investor base and are excited to have attracted a well-diversified group of new highly regarded institutional investors,” said Michael DiPiano, co-founder and Managing General Partner of NewSpring Capital.  The Fund’s Limited Partners consist of leading asset management firms, endowments, entrepreneurs, family offices, foundations, fund-of-funds, insurance companies and public pension plans.

NSG III will maintain its unique approach of partnering with leading growth stage businesses in the information technology, enabling technology and business services sectors, with an emphasis on the Mid-Atlantic region.  The NSG III investment team will leverage well established industry sourcing networks to identify and partner with the Mid-Atlantic region’s top entrepreneurs, providing capital and guidance to assist them in turning their visions into reality.  Successful historical partnerships include: eCount, Inc. {sold to Citigroup (NYSE: C)}, a leading electronic payments platform company; NitroSecurity, Inc. {sold to Intel Corporation (NASDAQ: INTC)}, a prominent provider of security information and event management solutions; Nutrisystem, Inc. (NASDAQ: NTRI), a leading ecommerce based weight loss provider and TMG Health, Inc. (sold to Health Care Service Corporation), a major business process outsourcing company focused on government sponsored health insurance plans.

Read more »

Science Accelerator: How to Apply for Funding

The Science & Technology Accelerator is tasked with identifying the most revolutionary, game-changing innovations, which are capable of dramatically improving cardiovascular health of millions of people, and assisting them from scientific validation through proof of concept. At that point, having been “de-risked” sufficiently, they can gain traction with industry or private equity sources of funding to take them to the finish line. In order to qualify for investment funding consideration, the inventor/innovator should be prepared to provide the following:

  • a brief explanation of how his or her innovation will improve cardiovascular health by dramatically reducing the incidence of heart attack and stroke; this explanation should be understandable by non-scientists
  • solid evidence of the scientific validity of the innovation, such as peer-reviewed publication(s)
  • proof of intellectual property ownership, such as patent application(s) in at least the U.S., as well as proof of freedom to operate
  • detailed development plans and regulatory strategy
  • business plan providing plausible timelines and route(s) to successful commercialization
  • size of investment requested and breakdown of exactly how it would be deployed
  • how and over what timeframe the AHA’s investment would be repaid

The Science & Technology Accelerator Program hopes to have raised sufficient funds by end of 1st quarter of 2013 to commence its next investment round with an announcement and request for proposals on the website below. If you believe your innovation could qualify for investment by the Science & Technology Accelerator Program, please watch for the announcement, and be prepared to provide the information listed above.

For more information, please Click Here.

Equipment, Facilities and Services Available from Rutgers University

Rutgers operates many highly sophisticated, world-class research facilities, such as a 3T MRI scanner, a 400-node radio grid testbed, and 96-well real-time PCR instrument that are available to researchers with commercial enterprises and other academic institutions.

Please CLICK HERE to view the complete list of available services and equipment.

If you are interested in any of the equipment/facilities/services please contact
the Facility Manager directly, or
The Rutgers Office of Research Alliances
Tel: 732-445-3344 E-mail: frontdoor@rutgers.edu

Executive Summary Template

BioNJ is pleased to offer an Executive Summary Template to guide and assist your company’s funding endeavors.

Please CLICK HERE to download the Executive Summary Template.